Compare VSEC & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VSEC | PTCT |
|---|---|---|
| Founded | 1959 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.5B |
| IPO Year | 1995 | 2006 |
| Metric | VSEC | PTCT |
|---|---|---|
| Price | $161.55 | $60.45 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 15 |
| Target Price | ★ $260.44 | $100.33 |
| AVG Volume (30 Days) | 436.4K | ★ 1.2M |
| Earning Date | 11-04-2026 | 10-29-2026 |
| Dividend Yield | ★ 0.25% | N/A |
| EPS Growth | N/A | ★ 264.48 |
| EPS | ★ 1.94 | 0.90 |
| Revenue | ★ $760,113,000.00 | $264,734,000.00 |
| Revenue This Year | $63.13 | N/A |
| Revenue Next Year | $21.44 | $9.47 |
| P/E Ratio | $83.54 | ★ $67.73 |
| Revenue Growth | 9.88 | ★ 36.19 |
| 52 Week Low | $152.34 | $58.80 |
| 52 Week High | $247.85 | $90.87 |
| Indicator | VSEC | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 38.22 | 34.61 |
| Support Level | $161.15 | N/A |
| Resistance Level | $186.49 | $68.93 |
| Average True Range (ATR) | 8.35 | 1.88 |
| MACD | 0.57 | -0.15 |
| Stochastic Oscillator | 39.41 | 13.26 |
VSE Corp is a diversified aftermarket products and services company serving commercial and government markets. The Company's operations include aircraft and airframe parts supply and distribution, and MRO services of aircraft components and engine accessories. The Company operates as a single reportable segment: Aviation, which is a provider of aftermarket parts distribution and MRO services for components and engine accessories supporting commercial, business, and general aviation operators.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.